Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm

Sho Kubota, PhD, Kenji Tokunaga, MD, Tomohiro Umezu, PhD, Takako Yokomizo, PhD, Motohiko Oshima, PhD, Eisaku Iwanaga, MD PhD, Norio Asou, MDPhD, Atsushi Iwama, MD PhD, Kazuma Ohyashiki, MD PhD, Motomi Osato, MD, PhD, Goro Sashida, MD PhD

Blood (2018) 132 (Supplement 1): 761.

https://doi.org/10.1182/blood-2018-99-110333

Published: 2018

Journal Articles

ASLAN003, a Novel and Potent Dihydroorotate Dehydrogenase (DHODH) Inhibitor, Induces Differentiation of Acute Myeloid Leukemia

Jianbiao Zhou, MD,PhD, Jessie Yiying Quah, B.S., Jing Yuan Chooi, BSc, Sabrina Hui-Min Toh, B.S., Yvonne Ng, B.S., Baohong Lin, B.S., Motomi Osato, MD, PhD, Qihui Seet, B.S., PhD, A.G. Lisa Ooi, B.S., PhD, Bertil Lindmark, MD PhD, Mark McHale, B.S., PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS

Blood (2018) 132 (Supplement 1): 4047.

https://doi.org/10.1182/blood-2018-99-114392

Published: 2018

Journal Articles

RUNX3 Promotes the Development of MDS/MPN Overlap Syndrome Via Enhancing Expression of Myc in the Absence of Tet2

Takako Yokomizo, PhD, Daiki Tanaka, Sho Kubota, PhD, Motohiko Oshima, PhD, Yuka Harada, MD PhD, Akinori Kanai, PhD, Atsushi Iwama, MD PhD, Hironori Harada, Motomi Osato, MD PhD, Goro Sashida, MD PhD

Blood (2017) 130 (Supplement 1): 2494.

https://doi.org/10.1182/blood.V130.Suppl_1.2494.2494

Published: 2017

Journal Articles

A Runx1 Interactome Identifies Novel Hematopoietic Enhancers

Judith Marsman, PhD, Amarni L Thomas, MSc, Motomi Osato, MD PhD, Justin M O'Sullivan, PhD, Julia A Horsfield, PhD

Blood (2016) 128 (22): 726.

https://doi.org/10.1182/blood.V128.22.726.726

Published: 2016

Journal Articles

Identification of Marker Genes That Discriminate between Different Myeloproliferative Disorders and Normal Individuals Including RUNX3 (AML2).

Claudia I. Muller, MD, Quang T. Luong, PhD, Letetia C. Jones, PhD, Julian C. Desmond, PhD, Norihiko Kawamata, MD, PhD, Tcherniantchouk Tcherniantchouk, MD, Lee-Yung Shih, MD, Yoshiaki Ito, MD, PhD, Kosei Ito, PhD, Qiang Liu, PhD, Motomi Osato, MD, PhD, Sven de Vos, MD, H. Phillip Koeffler, MD

Blood (2005) 106 (11): 3522.

https://doi.org/10.1182/blood.V106.11.3522.3522

Published: 2005

NARROW

Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm

ASLAN003, a Novel and Potent Dihydroorotate Dehydrogenase (DHODH) Inhibitor, Induces Differentiation of Acute Myeloid Leukemia

RUNX3 Promotes the Development of MDS/MPN Overlap Syndrome Via Enhancing Expression of Myc in the Absence of Tet2

A Runx1 Interactome Identifies Novel Hematopoietic Enhancers

Identification of Marker Genes That Discriminate between Different Myeloproliferative Disorders and Normal Individuals Including RUNX3 (AML2).

Email alerts

ASH Publications

American Society of Hematology

Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm

ASLAN003, a Novel and Potent Dihydroorotate Dehydrogenase (DHODH) Inhibitor, Induces Differentiation of Acute Myeloid Leukemia

RUNX3 Promotes the Development of MDS/MPN Overlap Syndrome Via Enhancing Expression of Myc in the Absence of Tet2

A Runx1 Interactome Identifies Novel Hematopoietic Enhancers

Identification of Marker Genes That Discriminate between Different Myeloproliferative Disorders and Normal Individuals Including RUNX3 (AML2).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only